Myomo Inc. (MYO)
| Market Cap | 46.96M |
| Revenue (ttm) | 5.31M |
| Net Income (ttm) | -13.30M |
| Shares Out | 3.94M |
| EPS (ttm) | -5.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $10.25 |
| Previous Close | $9.58 |
| Change ($) | 0.67 |
| Change (%) | 6.99% |
| Day's Open | 9.58 |
| Day's Range | 9.62 - 10.88 |
| Day's Volume | 284,318 |
| 52-Week Range | 3.00 - 24.50 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering f...
Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from ...
Myomo (MYO) is in the news Wednesday following an announcement about Medicare authorization that sent MYO stock soaring higher. The post Myomo News: MYO Stock Surges 32% on Medicare Authorizat...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
Myomo, Inc.'s (MYO) CEO Paul Gudonis on Q2 2020 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.50% and 43.17%, respectively, for the quarter ended June 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc.
Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2020 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -29.38% and 29.23%, respectively, for the quarter ended March 2020.
Myomo's (MYO) CEO Paul Gudonis on Q4 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -7.37% and 8.64%, respectively, for the quarter ended December 2019.
Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Myomo Inc (NYSE: MYO) shares ran wild Tuesday and the momentum continued in Wednesday's session.
Myomo, Inc. (MYO) CEO Paul Gudonis on Q3 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019.
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Myomo's (MYO) CEO Paul Gudonis on Q2 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Myomo, Inc. (MYO) CEO Paul Gudonis on Q1 2019 Results - Earnings Call Transcript
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 15.00% and -3.49%, respectively, for the quarter ended March 2019.
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
About MYO
Myomo, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace orthosis product used for supporting a patient's weak or paralyzed arm to enable and enhance functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injur... [Read more...]
| Industry Medical Devices | IPO Date Jun 12, 2017 |
| CEO Paul Gudonis | Employees 49 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol MYO |
Financial Performance
In 2019, Myomo's revenue was $3.84 million, an increase of 57.02% compared to the previous year's $2.44 million. Losses were -$10.71 million, 3.84% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Myomo stock is "Buy." The 12-month stock price forecast is 13.81, which is an increase of 34.73% from the latest price.